News

On 16 July, OHE will present a Lunchtime Seminar by Prof Peter Zweifel, who will discuss his recent research on patients' willingness to pay for pharmaceuticals. Space is limited at this seminar.

Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of 'traditional generics' is a poor guide; biosimilars possess critically different characteristics. In the seminar, Prof Grabowski explored these differences and presented his analyses of data exclusivity requirements for biologics/biosimilars.

A report published today by The King’s Fund shows that having a choice of hospitals is valued by the majority of patients. However, it is not yet operating as intended and has not so far acted as a lever to improve quality and increase competition.

On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market access strategy.

This is the second in our series of posts based on the OHE seminar on biosimilars and summarises the remarks of Prof Bengt Jönsson of the Stockholm School of Economics.

Pages